Division of Nephrology, Department of Medicine, Boston Children's Hospital-Harvard Medical School, 300 Longwood Avenue HU319, Boston, MA, 02115, USA.
Talpiot Medical Leadership Program, Sheba Medical Center, Tel-Hashomer, Israel.
Pediatr Nephrol. 2017 Dec;32(12):2273-2282. doi: 10.1007/s00467-017-3755-8. Epub 2017 Aug 5.
Rhabdomyolysis is a clinical emergency that may cause acute kidney injury (AKI). It can be acquired or due to monogenic mutations. Around 60 different rare monogenic forms of rhabdomyolysis have been reported to date. In the clinical setting, identifying the underlying molecular diagnosis is challenging due to nonspecific presentation, the high number of causative genes, and current lack of data on the prevalence of monogenic forms.
We employed whole exome sequencing (WES) to reveal the percentage of rhabdomyolysis cases explained by single-gene (monogenic) mutations in one of 58 candidate genes. We investigated a cohort of 21 unrelated families with rhabdomyolysis, in whom no underlying etiology had been previously established.
Using WES, we identified causative mutations in candidate genes in nine of the 21 families (43%). We detected disease-causing mutations in eight of 58 candidate genes, grouped into the following categories: (1) disorders of fatty acid metabolism (CPT2), (2) disorders of glycogen metabolism (PFKM and PGAM2), (3) disorders of abnormal skeletal muscle relaxation and contraction (CACNA1S, MYH3, RYR1 and SCN4A), and (4) disorders of purine metabolism (AHCY).
Our findings demonstrate a very high detection rate for monogenic etiologies using WES and reveal broad genetic heterogeneity for rhabdomyolysis. These results highlight the importance of molecular genetic diagnostics for establishing an etiologic diagnosis. Because these patients are at risk for recurrent episodes of rhabdomyolysis and subsequent risk for AKI, WES allows adequate prophylaxis and treatment for these patients and their family members and enables a personalized medicine approach.
横纹肌溶解症是一种可能导致急性肾损伤(AKI)的临床急症。它可以是获得性的,也可以是由于单基因突变引起的。迄今为止,已经报道了大约 60 种不同的罕见单基因形式的横纹肌溶解症。在临床环境中,由于表现不特异、致病基因数量多以及目前缺乏单基因形式流行率的数据,确定潜在的分子诊断具有挑战性。
我们采用外显子组测序(WES)来揭示在 58 个候选基因中的一个基因中,单基因(单基因)突变解释横纹肌溶解症病例的比例。我们研究了 21 个无关联的横纹肌溶解症家系的队列,这些家系之前没有确定潜在病因。
使用 WES,我们在 21 个家系中的 9 个(43%)中鉴定出候选基因中的致病突变。我们在 58 个候选基因中的 8 个基因中检测到致病突变,分为以下几类:(1)脂肪酸代谢紊乱(CPT2);(2)糖原代谢紊乱(PFKM 和 PGAM2);(3)异常骨骼肌松弛和收缩障碍(CACNA1S、MYH3、RYR1 和 SCN4A);和(4)嘌呤代谢紊乱(AHCY)。
我们的研究结果表明,使用 WES 对单基因病因的检测率非常高,并揭示了横纹肌溶解症的广泛遗传异质性。这些结果强调了分子遗传诊断对于确定病因诊断的重要性。由于这些患者有横纹肌溶解症反复发作和随后发生 AKI 的风险,WES 允许为这些患者及其家属进行适当的预防和治疗,并实现个性化医疗方法。